论文部分内容阅读
目的探讨莫西沙星治疗老年耐药性肺结核的临床疗效。方法选取新郑市中医院2013年6月—2015年6月收治的82例老年耐药性肺结核患者,按随机数字表法分为治疗组41例与对照组41例。对照组患者采用VDL2E方案治疗,即左氧氟沙星+氨基水杨酸异烟肼+利福喷丁+乙胺丁醇;治疗组患者采用MDL2E方案治疗,即莫西沙星+氨基水杨酸异烟肼+利福喷丁+乙胺丁醇。比较两组患者肺部病灶吸收情况、痰菌转阴情况、不良反应发生情况、临床疗效。结果治疗组总有效率高于对照组,不良反应发生率低于对照组,肺部吸收情况优于对照组、痰菌转阴率高于对照组,差异有统计学意义(P<0.05)。结论莫西沙星治疗老年耐药性肺结核的临床疗效确切,有助于减少不良反应,提高痰菌转阴率。
Objective To investigate the clinical efficacy of moxifloxacin in the treatment of elderly drug-resistant pulmonary tuberculosis. Methods Eighty-two elderly patients with drug-resistant pulmonary tuberculosis admitted to Xinzheng Hospital of Traditional Chinese Medicine from June 2013 to June 2015 were divided into treatment group (41 cases) and control group (41 cases) by random number table. Patients in the control group were treated with VDL2E regimen, that is, levofloxacin + isoniazid aminosalicylate + rifapentine + ethambutol; patients in the treatment group were treated with the MDL2E regimen, ie moxifloxacin + isoniazid + Rifampicin + ethambutol. The lung lesions absorption, sputum negative conversion, adverse reactions and clinical effects were compared between the two groups. Results The total effective rate of the treatment group was higher than that of the control group, the incidence of adverse reactions was lower than that of the control group, the lung absorption was superior to the control group, and the sputum negative conversion rate was higher than that of the control group (P <0.05). Conclusion Moxifloxacin treatment of elderly drug-resistant tuberculosis clinical curative effect is exact, help to reduce adverse reactions and improve sputum negative rate.